SUMMARY A boy investigated for neonatal jaundice was noted to have lipaemic serum and was subsequently shown to have type V hyperlipo-
example, to differential recall of asthma or eczema between 1 and 5 years of age by parents of children who received breast or bottle feeds in the first 4 weeks. The high response rate made it unlikely that biases could be the result of differential drop out rates.
No evidence was found for an association between type of feeding and development of asthma in the first 5 years. There is, however, a significant association between family history of atopy and risk of the child developing asthma by the age of 5.
Studies of the aetiology of eczema tend to lack precision in the definition of eczema and accurate recording of the infant's diet. It is worrying that in this motivated and cooperative group of parents with a low drop out rate, recall at five years of eczema during the first year was relatively poor, even though the eczema was diagnosed and discussed with them by a doctor whom they saw regularly. This must have implications for studies relying exclusively on parental recall for evidence of eczema in infancy.
proteinaemia. Dietary treatment was maintained for five years and he followed a typical clinical course. Circumstantial evidence suggested an autosomal recessive inheritance pattern.
Type V hyperlipoproteinaemia is rare in childhood and has not to our knowledge been described in a neonate. hyperlipoproteinaemia.1 Lipoprotein electrophoretoPlasma post-heparin lipoprotein lipase activity at grams usually showed a type V pattern although the age of 5 was normal, free fatty acid release from occasional type IV patterns were noted. a synthetic triolein emulsion in low salt medium Table 2 summarises his current diet. He remained being [7] [8] [9] [10] [11] [12] [13] [14] Zmol/mUhour and in high salt medium well after his episode of pancreatitis apart from two 11 76 pmol/ml/hour compared with adult control brief recurrences of eruptive xanthomata on recent values of 6-77 and 8-27, respectively: plasma was holidays. Serum lipoprotein concentrations were not collected 10 minutes after intravenous injection of measured during these episodes, but an increase in heparin 10 U/kg.7 Serum apolipoprotein C-IL, refined carbohydrate intake preceded each one. C-11l, and C-1112 concentrations determined by Growth has been normal and soft tissue swelling, as polyacrylamide gel electrophoresis of very low described by Deckelbaum et al, has not been noted.4 density lipoprotein apolipoproteins in 8 M urea were 
Discussion
The patient's clinical features are typical of both types I and V hyperlipoproteinaemia. The plasma lipid profile at 2 months of age strongly suggested the diagnosis of type V hyperlipoproteinaemia but did not exclude type I, which is a disorder seen more commonly in neonates. Familial apolipoprotein C-I1 deficiency is recessively inherited and may result in clinical and lipid profiles similar to those of type V hyperlipoproteinaemia. Normal PHLPL activity and apolipoprotein gel electrophoresis excluded these alternative diagnoses. ' Familial type V hyperlipoproteinaemia is probably an expression of several different genotypes.2 Autosomal dominant inheritance had been well defined in some pedigrees but in other familial cases the inheritance pattern is not clear. 5 Greenberg et al.6 described a patient who was the child of a marriage of first cousins; the parents phenotypes were unfortunately not documented. Kwiterovich et a12 suggested autosomal recessive inheritance with variable expression of heterozygosity as a possible explanation for some pedigrees. No obligate heterozygotes had manifest type V hyperlipoproteinaemia in the pedigree described here; neonatal onset accompanied by negative but consanguineous family history suggests an autosomal recessive inheritance pattern.
The pathogenesis of type V hyperlipoproteinaemia has not been adequately explained, although a defect in clearance of very low density lipoprotein cholesterol has been proposed as the primary abnormality.' Because of early onset and presumed autosomal recessive inheritance, this boy's primary defect probably differs from those of reported cases of type V hyperlipoproteinaemia and suggests aetiological heterogeneity of the disorder. ' For treatment of type V hyperlipoproteinaemia moderate dietary restriction (335 MJ in 24 hours for adults), restriction of regular fat (25-30% of MJ), moderate restriction of total carbohydrate (40-50% of MJ), and medium chain triglyceride supplements are recommended. 1-2 Symptoms in this case dictated more severe dietary fat restriction. The recurrence of symptoms after an increase in refined carbohydrate intake without change in fat intake suggested the need for specific restriction of this form of carbohydrate. Treatment at the time of writing is therefore based on a diet that limits long chain triglycerides to about 1-5 g/kg in 24 hours and eliminates refined carbohydrate without restricting total calories. Medium chain triglyceride oil is used for cooking as a caloric supplement, but has not affected the plasma lipid profile. 
